Skip to content

concannon research lab

Dr. Concannon aims for his research focus to remain the same as his earlier work, overcoming resistance in lung cancer, figuring out why treatments do not work, and getting to the crux of the genetic component to the disease that leaves people feeling helpless. Specifically, Dr. Concannon's lab plans to investigate driver mutations in lung cancer starting with ALK-positive and ROS1-positive NSCLC. Cancer patients who have an oncogene can have a unique susceptibility to certain therapies that work well, but only for a short period of time, overcoming resistance in those contexts is the bigger picture.

cracking cancer

Cracking Cancer, is a podcast dedicated to breaking down the knowledge and cultural barriers between patients and healthcare providers. Its mission is to empower listeners with clear, accessible insights into cancer care and treatment options. Through expert interviews, patient stories, and Q&A, Cracking Cancer aims to create a more informed and supportive cancer community. Since the podcast launched in February 2025, the podcast videos have been screened nearly 27,000 times.

lab personnel

selected publications

Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024 Feb 12;42(2):225-237.e5. doi: 10.1016/j.ccell.2024.01.001. Epub 2024 Jan 25. PMID: 38278149; PMCID: PMC10982990.

Serrano AG, Rocha P, Freitas Lima C, Stewart A, Zhang B, Diao L, Fujimoto J, Cardnell RJ, Lu W, Khan K, Sable B, Ellison AR, Wistuba II, Concannon KF, Halperin DM, Bogdan C, Sircar K, Zhang M, Cargill K, Wang Q, Aparicio A, Lazar A, Hernandez S, Estrella J, Ramalingam P, El-Naggar A, Kalhor N, Gay CM, Byers LA, Solis Soto LM. Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms. NPJ Precis Oncol. 2024 Nov 19;8(1):268. doi: 10.1038/s41698-024-00739-y. PMID: 39558076; PMCID: PMC11574146.

Morris BB, Heeke S, Xi Y, Diao L, Wang Q, Rocha P, Arriola E, Lee MC, Tyson DR, Concannon K, Ramkumar K, Stewart CA, Cardnell RJ, Wang R, Quaranta V, Wang J, Heymach JV, Nabet BY, Shames DS, Gay CM, Byers LA. DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancer. Mol Cancer. 2025 Mar 20;24(1):90. doi: 10.1186/s12943-025-02291-0. PMID: 40114214; PMCID: PMC11924755.

View all publications

Medical Oncology

CU Anschutz

Research I South

12801 East 17th Avenue

8122

Aurora, CO 80045

720-848-0300

Facebook Twitter

Search